Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Broker Ratings Changes Drive FTSE 100 Movers

Mon, 23rd Mar 2015 11:22

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Monday.
-------
FTSE 100 WINNERS
-------
Standard Chartered, up 5.1%. JP Morgan has raised the emerging markets bank to Overweight from Neutral.
-------
FTSE 100 LOSERS
-------
Carnival, down 2.8%. Deutsche Bank has downgraded the cruise operator to Hold from Buy.

Meggitt, down 1.9%. Bernstein has downgraded the engineer of components for the aerospace, defence and energy markets to Market-Perform from Outperform, according to traders.
-------
FTSE 250 WINNERS
-------
Centamin, up 14%. The Egypt-focused gold miner reported a sharp drop in pretax profit for 2014 as the falling gold price offset a rise in production, but the company still declared a dividend for the year. Centamin said its pretax profit for the year was USD81.6 million, less than half the USD184 million it posted a year earlier. Revenue dropped to USD472.6 million from USD503.8 million. However, the company proposed a final dividend of 1.99 US cents per share, giving it a total payout of 2.86 cents per share for the year. Centamin paid no dividend in 2013.

FirstGroup, up 3.8%. The transport operator said it had retained the First Great Western rail franchise in the UK until at least April 2019, and pledged to add new and updated trains, faster services, more direct trains to Devon and Cornwall and improvements to infrastructure. The company said it will continue the franchise until April 1, 2019, and the deal could be extended for a further year at the UK government's discretion. It has already been running the franchise since 2006.

Vedanta Resources, up 2.4%. JP Morgan has raised the miner's price target to 520.00 pence from 450.00p. The stock currently trades at 537.50p.

Pennon Group, up 1.8%. The water utility and waste management company said trading remains in line with expectations for its financial year to the end of March, with its South West Water business performing well and its Viridor waste management division making progress, leading the company to reiterate its dividend growth plans. It said it is well placed to generate increasing operating cashflows over the 2015-2020 regulatory period and, as a result, intends to continue with its current dividend policy of year-on-year growth of 4% above UK retail prices index inflation over that period.
-------
AIM ALL-SHARE WINNERS
-------
Silence Therapeutics, up 22%. The company said it had seen an "excellent outcome" in its Phase IIa trial of compound Atu027 in pancreatic cancer. The primary objective of the trial was to assess the safety and pharmacokinetics of the compound, and the second objective was to evaluate its efficacy including progression free survival.

Verona Pharma, up 21%. The company said it has seen "very encouraging" initial interim results from its ongoing phase I/II clinical trial with a new nebulised formulation of its RPL554 compound. Results from the first part of the study showed the drug was well tolerated across all doses tested, and no maximum tolerated dose could be defined. It noted that there were no changes in the subject's cardiovascular parameters, and a complete absence of nausea or vomiting at all doses.

Metal Tiger, up 19%. The company said it has now implemented its divisional restructuring and is in the position to self-finance its activities. The company said its two new investment divisions, Direct Equities and Direct Projects, are now embedded and fully operational. It had said in Late January it was to create the new structure as part of an updated strategic approach.

Premaitha Health, up 16%. The company said it has been awarded a three-year contract to provide its non-invasive prenatal test, known as IONA, to St George's University Hospitals NHS Foundation Trust. The test is currently the subject of a patent infringement suit filed by NASDAQ listed Illumina Inc last Monday. The contract was awarded following a competitive tender process, and St George's Hospital in South West London will be the first National Health Service facility to offer non-invasive prenatal testing in-house.
-------
AIM ALL-SHARE LOSERS
-------
Clean Air Power, off 31%. The company reported a sharp drop in revenue and an increase in cash consumption in 2014 and warned that 2015 would also be challenging as it seeks fresh funding to shore up an uncertain financial future. Clean Air Power said it faces significant doubt over whether it can continue in business unless it secures additional funding. It said it now has limited means to further cut costs, and is now seeking fresh funding through either a second major deal with a manufacturer, which would boost cash flow, or "alternative sources of funding". It said talks are ongoing with a number of manufacturers.

SpaceandPeople, down 15%. The marketing company said its pretax profit dropped in 2014 as a rise in its cost of sales outpaced revenue growth and said it would slash its dividend. It said its pretax profit fell to GBP596,000 from GBP1.8 million a year earlier.

Egdon Resources, down 10%. Europa Oil & Gas and Egdon Resources said they have plugged and abandoned the Kiln Lane-1 exploration well in the East Midlands of England and will return the site to farmland after drilling encountered sandstones with too much water.
-------

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
7 Mar 2014 09:39

Friday broker round-up UPDATE

AGA Rangemaster: N+1 Singer ups target price from 175p to 192p and maintains a buy recommendation. Aggreko: JP Morgan lowers target price from 1542p to 1536p and maintains a neutral rating. Goldman Sachs increases target price from 1876p to 1950p and keeps a buy recommendation. Numis upgrades to re

Read more
6 Mar 2014 18:02

Verona Pharma Looks To Raise Up To GBP14 Million In Share Placing

LONDON (Alliance News) - Verona Pharma PLC Thursday said it intends to raise up to GBP14 million before expenses in a share placing, subscription, and open offer, which it said it will use to fund further development of its RPL554 drug. The drug development company focuses on medicines to t

Read more
11 Nov 2013 08:50

Monday broker round-up UPDATE

Associated British Foods: Barclays downgrades to equal-weight with a target price of 2100p. Bovis Homes Group: Deutsche Bank moves target price from 1001p to 1008p maintaining a buy recommendation. British Land: Deutsche Bank downgrades to sell with a target price of 520p. British Sky Broadcastin

Read more
25 Oct 2013 08:35

Verona Pharma Says RPL554 Drug Trial Positive

Read more
30 Sep 2013 12:47

Verona Pharma Widens Losses As Treatment Development Continues

Read more
5 Sep 2013 09:37

Verona Pharma Appoints Chroma CEO Bungay As New Part-Time CFO

Read more
5 Sep 2013 08:15

Verona Pharma replaces CFO Lowe with Bungay

Verona Pharma on Thursday said Chief Financial Officer (CFO) Danny Lowe would be replaced by Richard Bungay with immediate effect. Bungay will work part-time at the respiratory treatments specialist at first and Lowe will work with him for an interim period to make sure there is a smooth handover.

Read more
23 Jul 2013 16:21

SABMilller Chairman sells over 11m pounds in shares

Graham Mackay, the Chairman of SABMiller who is currently on a medical leave of absence due to a brain tumour, has sold over 11m pounds-worth of shares in the company. Mackay sold a total of 350,000 shares between July 16-18th through three separate transactions, the firm revealed on Tuesday. He so

Read more
26 Apr 2013 15:09

Advanced Oncotherapy CEO makes triple purchase

The Chief Executive of Advanced Oncotherapy, a provider of new technology for innovative and patient-focused cancer treatments, has this week purchased three lots of shares in the group, taking his stake to just under 69.4m shares. On Thursday Sinclair purchased one round of 8.075m shares at 1.59p

Read more
10 Apr 2013 16:27

AZ Electronic Materials directors try to minimize damage

John Whybrow, the Chairman of AZ Electronic Materials, which on Tuesday tanked after it issued a warning on full year revenue, has shown his faith in the chemicals company by enlarging his shareholding. Whybrow acquired 40,000 shares at 254p each for a total trade value of £101,600, taking his sta

Read more
4 Sep 2012 08:58

Small caps round-up: Verona, Image Scan, Avia

Respiratory diseases specialist Verona Pharma has hailed a positive outcome of a clinical trial of its lead drug candidate, the snappily-named RPL554. The data showed that a single dose of RPL554 in spray form administered to patients with chronic obstructive pulmonary disease (COPD) produced a ra

Read more
28 Aug 2012 14:43

Small caps round-up: Transense Tech, Hightex, Verona Pharma

Transense Technologies, which provides sensor systems for the transportation and industrial markets, has reported that its trading division, Translogik, has received an initial order for its iTrack Tyre Temperature and Pressure Monitoring Systems for mining and off-the-road vehicles from its Indones

Read more
9 Jul 2012 10:25

Small caps round-up: Lighthouse, Verona Pharma, Manroy...

Shares in Lighthouse Group, the financial advice and wealth management group, plunged on Monday after the company proposed to cancel its listing on AIM. The group must receive approval from shareholders representing at least three-quarters of the company's shares for the cancellation to be approved.

Read more
26 Nov 2010 15:56

Small caps round-up: Verona Pharma, PHSC, Sterling Green

Verona Pharma, respiratory diseases treatment developer, is initiating a new higher dose trial of its lead drug, RPL554, in patients with asthma, after receiving the go-ahead from the Dutch authorities. The company also announced that it has completed proof of concept trials on delivering RPL554 vi

Read more
28 Jun 2010 07:33

Verona Pharma In Talks With Licensees For RPL554 Cough Project

LONDON (Dow Jones)--Verona Pharma PLC (VRP.LN), an AIM quoted drug discovery company, said Monday licensing discussions continue to advance with potential licensees for its RPL554 cough project and it plans three clinical trials to add value to licensing package for RPL554. MAIN FACTS: -Has

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.